[
    [
        {
            "time": "2018-04-05",
            "original_text": "After Hours Most Active for Apr 5, 2018: CZR, MSFT, KEY, JPM, CSCO, CMCSA, MU, MXIM, GE, NUE, ABBV, PFE",
            "features": {
                "keywords": [
                    "Most Active",
                    "CZR",
                    "MSFT",
                    "ABBV",
                    "JPM"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "finance",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "After Hours Most Active for Apr 5, 2018: CZR, MSFT, KEY, JPM, CSCO, CMCSA, MU, MXIM, GE, NUE, ABBV, PFE",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "MARKETS: Stocks bust higher, Facebook fake out, Boeing bump, financials turn green",
            "features": {
                "keywords": [
                    "Stocks",
                    "higher",
                    "Facebook",
                    "Boeing",
                    "financials",
                    "green"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "aerospace",
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "MARKETS: Stocks bust higher, Facebook fake out, Boeing bump, financials turn green",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Humira",
                    "Biosimilars",
                    "Settles"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "Tracking the traders' Q1 moves",
            "features": {
                "keywords": [
                    "traders",
                    "Q1",
                    "moves"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Tracking the traders' Q1 moves",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Samsung",
                    "Bioepis",
                    "Humira",
                    "biosimilar",
                    "U.S.",
                    "release",
                    "2023"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "AbbVie Deal Allows Biogen To Launch Humira Copy In Europe",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Biogen",
                    "Humira",
                    "Europe"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Deal Allows Biogen To Launch Humira Copy In Europe",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Biogen",
                    "Humira",
                    "biosimilar",
                    "U.S.",
                    "launch",
                    "2023"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 9,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "HUMIRA",
                    "Patent",
                    "Disputes",
                    "Samsung",
                    "Bioepis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 10,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-04-05",
            "original_text": "Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization",
            "features": {
                "keywords": [
                    "Biogen",
                    "Samsung",
                    "Bioepis",
                    "Abbvie",
                    "Imraldi",
                    "Commercialization"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Biogen, Samsung Bioepis Announce Deal With Abbvie For Imraldi Commercialization",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]